Catridecacog Enrolling by Invitation Phase N/A Trials for Congenital Hematological Disorder / Congenital FXIII Deficiency

IndicationsStatusPurposePhase
Enrolling by InvitationNot AvailableNot Available
clinicaltrials.gov IdentifierTitleDrugs
NCT02670213A Study of Safety and Effectiveness of NovoThirteen® (rFXIII) During Treatment of Congenital FXIII Deficiency in Japan